Literature DB >> 11179282

Acute pulmonary embolism 2: treatment.

M Riedel1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11179282      PMCID： PMC1729663          DOI： 10.1136/heart.85.3.351

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  7 in total

1.  A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire.

Authors:  G Simonneau; H Sors; B Charbonnier; Y Page; J P Laaban; R Azarian; M Laurent; J L Hirsch; E Ferrari; J L Bosson; D Mottier; B Beau
Journal:  N Engl J Med       Date:  1997-09-04       Impact factor: 91.245

Review 2.  Antithrombotic therapy for venous thromboembolic disease.

Authors:  T M Hyers; G Agnelli; R D Hull; J G Weg; T A Morris; M Samama; V Tapson
Journal:  Chest       Date:  1998-11       Impact factor: 9.410

Review 3.  Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.

Authors:  J Hirsh; J E Dalen; D R Anderson; L Poller; H Bussey; J Ansell; D Deykin; J T Brandt
Journal:  Chest       Date:  1998-11       Impact factor: 9.410

4.  Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group.

Authors:  R D Hull; G E Raskob; R F Brant; G F Pineo; G Elliott; P D Stein; A Gottschalk; K A Valentine; A F Mah
Journal:  Arch Intern Med       Date:  2000-01-24

5.  Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry.

Authors:  S Konstantinides; A Geibel; M Olschewski; F Heinrich; K Grosser; K Rauber; S Iversen; M Redecker; J Kienast; H Just; W Kasper
Journal:  Circulation       Date:  1997-08-05       Impact factor: 29.690

Review 6.  Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.

Authors:  J Hirsh; T E Warkentin; R Raschke; C Granger; E M Ohman; J E Dalen
Journal:  Chest       Date:  1998-11       Impact factor: 9.410

7.  Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study.

Authors:  C Théry; G Simonneau; G Meyer; O Hélénon; F Bridey; C Armagnac; P d'Azemar; J P Coquart
Journal:  Circulation       Date:  1992-04       Impact factor: 29.690
  7 in total
  1 in total

1.  Timely embolectomy in acute massive pulmonary embolism prevents catastrophe: An experience from two cases.

Authors:  Dwarakaprasad Ramesh; Huliyurdurga Srinivasasetty Natraj Setty; Sunil Kumar; Cholenahalli Nanjappa Manjunath
Journal:  J Nat Sci Biol Med       Date:  2016 Jul-Dec
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.